OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Sotagliflozin (Sota) inhibits sodium glucose cotransporter 2 (SGLT2; IC(50)=1.8 nM) and SGLT1 (IC(50)=36 nM). In humans, Sota improves glycemic control in part by increasing urinary glucose excretion via renal SGLT2 inhibition. Sota also lowers postprandial glucose (PPG), likely by inhibiting intest...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Endocr Soc
Huvudupphovsmän: Powell, David, Zambrowicz, Brian, Morrow, Linda, Beysen, Carine, Hompesch, Marcus, Turner, Scott, Hellerstein, Marc, Banks, Phillip, Strumph, Paul, Lapuerta, Pablo
Materialtyp: Artigo
Språk:Inglês
Publicerad: Endocrine Society 2019
Ämnen:
Diabetes Mellitus and Glucose Metabolism
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555054/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR22-5
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk